Aflibercept (Eylea, BAY86-5321)

DRUG13 trials

Sponsors

Bayer

Conditions

Central Retinal Vein OcclusionChoroidal NeovascularizationDiabetic Macular Edema (DME)Glaucoma, NeovascularInfantsMacular DegenerationMacular EdemaNeovascular Age-related Macular Degeneration (nAMD)

Phase 3

Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied

CompletedNCT03639675

BayerGlaucoma, Neovascular

Start: 2018-10-03End: 2019-03-14Updated: 2020-03-03

Phase 4

Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO

CompletedNCT02800642

BayerCentral Retinal Vein Occlusion

Start: 2016-06-10End: 2019-07-31Updated: 2020-07-08

Unknown Phase

Special Drug Use Investigation of EYLEA for Diabetic Macular Edema

CompletedNCT02425501

BayerMacular Edema

Start: 2015-01-20End: 2019-08-13Updated: 2023-01-11

Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion

CompletedNCT02645747

BayerRetinal Vein Occlusion

Start: 2016-01-21End: 2017-12-23Updated: 2018-09-06

Prospective Observational Study to Assess Effectiveness of Intravitreal Aflibercept in Patients With Wet Macular Degeneration in Greece

CompletedNCT02821247

BayerChoroidal Neovascularization, Macular Degeneration

Start: 2016-07-01End: 2019-12-13Updated: 2020-11-25

A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their Disease

CompletedNCT03161912

BayerMacular Edema

Start: 2017-11-24End: 2021-12-17Updated: 2022-11-14

The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical Setting

CompletedNCT03278262

BayerWet Macular Degeneration

Start: 2017-09-01End: 2017-12-31Updated: 2018-10-29

Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice

CompletedNCT03290794

BayerWet Age-related Macular Degeneration

Start: 2019-02-14End: 2023-05-26Updated: 2023-06-09

Observational Study to Assess Intravitreal Aflibercept Injections Used in a Treat and Extend Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients

CompletedNCT03382587

BayerWet Age-related Macular Degeneration

Start: 2017-12-05End: 2018-11-27Updated: 2023-06-05

Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease

CompletedNCT03939767

BayerWet Age-related Macular Degeneration

Start: 2019-05-12End: 2023-10-17Updated: 2024-09-20

Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)

RecruitingNCT04519619

BayerNeovascular Glaucoma

Start: 2020-11-27End: 2028-06-30Target: 480Updated: 2026-06-30

A Study to Collect Data on the Use of Eylea in Babies Born Too Early Who Have a Condition of the Eye Where Blood Vessels Grow Abnormally in the Retina (Retinopathy of Prematurity)

Active, not recruitingNCT05705258

BayerInfants, Newborns, Retinopathy of Prematurity

Start: 2023-03-27End: 2027-03-30Target: 75Updated: 2026-07-06

A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema

Active, not recruitingNCT06929143

BayerDiabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (nAMD)

Start: 2025-04-14End: 2027-07-30Target: 3000Updated: 2026-05-12

Related Papers

Real-World Intravitreal Aflibercept 2 mg Treatment of Macular Oedema Secondary to Retinal Vein Occlusion in Italy: 24-Month Results from the AURIGA Observational Study

Ophthalmologica2025-04-091 citations

2-year results from an observational study of proactive treatment regimens with intravitreal aflibercept 2 mg in patients with nAMD in clinical practice: XTEND study UK cohort.

2024-12-241 citations

XTEND: Two-Year Results from a Global Observational Study Investigating Proactive Dosing of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration.

2024-01-103 citations

Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema in Routine Clinical Practice: Results from the 24-Month AURIGA Observational Study.

2023-11-048 citations

Real-World Management of Macular Edema Secondary to Retinal Vein Occlusion with Intravitreal Aflibercept: 24-month Results from the AURIGA Observational Study.

2023-11-046 citations

Intravitreal aflibercept for diabetic macular edema in real-world clinical practice in Japan: 24-month outcomes.

2022-06-0214 citations

Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend for Macular Edema in Central Retinal Vein Occlusion: the CENTERA Study.

2021-02-0623 citations

Efficacy and Safety of Intravitreal Aflibercept Injection in Japanese Patients with Neovascular Glaucoma: Outcomes from the VENERA Study.

2020-12-1611 citations